Not all people with CLL demand therapy. Even with all current improvements, the iwCLL nonetheless endorses watchful observation for individuals with asymptomatic illness.86 This advice relies on at least two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR).103,104 The two trials concluded that early https://teresae702hgf4.wikigop.com/user